Hpv Vaccines Market Scope And Analysis

Report Code : TIPRE00029411
Category : Pharmaceuticals

Status : Published
No. of Pages : 277

Buy Now

Human Papillomavirus (HPV) Vaccine Market Scope, Analysis, and Trends by 2028

Buy Now

Human Papillomavirus (HPV) Vaccine Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 4.27 Billion
Market Size by 2028	US$ 5.73 Billion
Global CAGR (2022 - 2028)	5.0%
Historical Data	2020-2021
Forecast period	2023-2028
Segments Covered	By Type 9-Valent HPV Vaccine Quadrivalent HPV Vaccine Bivalent HPV Vaccine By Dosage 2 Dose and 3 Dose By Age 9 to 14 Years and 15 to 45 Years By Application HPV-Attributable Cancer and Genital Warts
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Merck Co In GSK Serum Institute of India Walvax Biotechnologies Innova Vaccitech Innovio Pharmaceuticals Chengdu Institute of Biological Products Co Ltd Sanofi

Companies commonly adopt product launches and expansion strategies to expand their footprint worldwide, meet the growing demand, and expand their product portfolio. The players operating in the global human papillomavirus (HPV) vaccine market implement the strategy of product innovation for changing customer demand worldwide, which also permits them to maintain their brand name globally.

In May 2022, China’s National Medical Products Administration (NMPA) approved GlaxoSmithKline’s (GSK) two-dose vaccine schedule, Cervarix, in girls from 9 to 14 years to prevent cervical cancer. Cervarix is a recombinant, noninfectious, AS04-adjuvanted HPV bivalent (types 16, 18) vaccine.
n May 2022, Serum Institute of India announced the development of a tetravalent HPV vaccine including L1 VLPs of serotypes 6,11,16,18, which is expected to give a coverage of ~90% against papillomavirus. The vaccine is currently under development.
In May 2020, Shanghai Bovax Biotechnology collaborated with Chongoing Bovax Biopharmaceutical to evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccines.

By geography, the human papillomavirus (HPV) vaccine market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, Russia, Belarus, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, Southeast Asia, New Zealand, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, Iran, Turkey, Kuwait, Bahrain, Egypt, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, Chile, Guatemala, Peru, Colombia, and the Rest of South & Central America). GSK; Innovax; Walvax; Serum Institute of India Pvt., Ltd.; Vaccitech; Innovio Pharmaceuticals; Merck & Co., Inc.; 2A Pharm; ChengDu Institute of Biological Products Co., Ltd.; Sanofi; R-Pharm; Shanghai Bowei; and BioLeaders are among the leading companies operating in the market.